Designation of Pegaspargase (Oncaspar) as an orphan drug - Link Medical Products

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and use of therapeutic goods in Australia. The Act was introduced to address the need for a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods available to consumers. The Act provides the legal foundation for the Therapeutic Goods Administration (TGA) to carry out its regulatory functions. This specific designation under the Therapeutic Goods Act 1989, announced on 24 April 2015, identifies Pegaspargase (Oncaspar) as an orphan drug for the treatment of patients with acute lymphoblastic leukaemia. The policy objective behind this designation is to encourage the development of treatments for rare diseases by providing incentives to manufacturers, such as streamlined regulatory processes and potential market exclusivity. This action by the Delegate of the Secretary, Dr Anthony Gill, was taken under the authority of the Therapeutic Goods Regulations 1990, which provide the detailed mechanisms for implementing the Act’s provisions.

Scope and Application

The Therapeutic Goods Act 1989, as amended and supplemented by the Therapeutic Goods Regulations 1990, governs the designation of certain therapeutic goods in Australia. This includes the designation of orphan drugs, which are specifically designated to treat rare medical conditions. In this context, the Act and its subordinate regulations facilitate the designation of Pegaspargase (ONCASPAR) as an orphan drug for the treatment of patients with acute lymphoblastic leukaemia (ALL). This legislative framework applies to the sponsor of the drug, in this instance, Link Medical Products, and the therapeutic good itself, Pegaspargase (ONCASPAR), intended for a specific medical indication. The application of the Act is national in scope, aligning with the Commonwealth's jurisdiction over therapeutic goods. The specific designation of an orphan drug does not exclude any particular entities or individuals from the application of the Act; rather, it ensures that the therapeutic good meets the criteria set forth for such a designation. Additionally, the Act can extend its application through subordinate instruments, allowing for further clarification and specification of the conditions and processes involved in the designation of orphan drugs.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as demonstrated in the designation of Pegaspargase (Oncaspar) as an orphan drug, involve the application and approval process for therapeutic goods that meet the criteria for orphan drug designation (sections 16J and subregulation 16J(2) of the Therapeutic Goods Regulations 1990). Under this legislation, the Delegate of the Secretary has the authority to designate a drug as an orphan drug if it is intended for the treatment of a rare disease, in this case, acute lymphoblastic leukaemia (ALL). The designation acknowledges the rarity of the condition and the importance of incentivising the development of treatments for such conditions. This specific designation pertains to the solution for injection form of Pegaspargase (Oncaspar) and identifies Link Medical Products as the sponsor responsible for the therapeutic good. The obligations and requirements imposed by the Act on the parties involved include ensuring that the therapeutic good meets the necessary standards and is safe for use. The sponsor, in this case, Link Medical Products, must provide adequate evidence and documentation to support the orphan drug designation. This includes demonstrating that the drug is intended for a rare condition and that it will offer significant benefit over existing treatments. Additionally, the sponsor must comply with any further requirements or conditions stipulated by the Therapeutic Goods Administration, such as providing ongoing safety and efficacy data post-market. Failure to comply with the requirements set out in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to serious consequences. Offences under the Act can include the unauthorised use of therapeutic goods, failure to comply with labelling requirements, or the provision of misleading information regarding the therapeutic goods. The penalties for breaches can vary, but in some cases, they can include substantial fines. For example, individuals may face fines of up to $222,200, while corporations may face fines of up to $1,111,000. In addition to financial penalties, there can be civil and criminal consequences, including the possibility of imprisonment for serious or repeated offences. These provisions are designed to ensure the safety and efficacy of therapeutic goods available in the Australian market.